The sense of hearing is essential for permitting human beings to interact with the environment, and its dysfunctions can strongly impact on the quality of life. In this context, the cochlea plays a fundamental role in the transformation of the airborne sound waves into electrical signals, which can be processed by the brain. However, several diseases and external stimuli (e.g., noise, drugs) can damage the sensorineural structures of cochlea, inducing progressive hearing dysfunctions until deafness. In clinical practice, the current pharmacological approaches to treat cochlear diseases are based on the almost exclusive use of systemic steroids. In the last decades, the efficacy of novel therapeutic molecules has been proven, taking advantage from a better comprehension of the pathological mechanisms underlying many cochlear diseases. In addition, the feasibility of intratympanic administration of drugs also permitted to overcome the pharmacokinetic limitations of the systemic drug administration, opening new frontiers in drug delivery to cochlea. Several innovative drug delivery systems, such as in situ gelling systems or nanocarriers, were designed, and their efficacy has been proven in vitro and in vivo in cochlear models. The current review aims to describe the art of state in the cochlear drug delivery, highlighting lights and shadows and discussing the most critical aspects still pending in the field.
Innovative pharmaceutical approaches for the management of inner ear disorders / U.M. Musazzi, S. Franzé, F. Cilurzo. - In: DRUG DELIVERY AND TRANSLATIONAL RESEARCH. - ISSN 2190-393X. - 8:2(2018 Apr), pp. 436-449. [10.1007/s13346-017-0384-5]
Innovative pharmaceutical approaches for the management of inner ear disorders
U.M. Musazzi
Primo
;S. FranzéSecondo
;F. CilurzoUltimo
2018
Abstract
The sense of hearing is essential for permitting human beings to interact with the environment, and its dysfunctions can strongly impact on the quality of life. In this context, the cochlea plays a fundamental role in the transformation of the airborne sound waves into electrical signals, which can be processed by the brain. However, several diseases and external stimuli (e.g., noise, drugs) can damage the sensorineural structures of cochlea, inducing progressive hearing dysfunctions until deafness. In clinical practice, the current pharmacological approaches to treat cochlear diseases are based on the almost exclusive use of systemic steroids. In the last decades, the efficacy of novel therapeutic molecules has been proven, taking advantage from a better comprehension of the pathological mechanisms underlying many cochlear diseases. In addition, the feasibility of intratympanic administration of drugs also permitted to overcome the pharmacokinetic limitations of the systemic drug administration, opening new frontiers in drug delivery to cochlea. Several innovative drug delivery systems, such as in situ gelling systems or nanocarriers, were designed, and their efficacy has been proven in vitro and in vivo in cochlear models. The current review aims to describe the art of state in the cochlear drug delivery, highlighting lights and shadows and discussing the most critical aspects still pending in the field.File | Dimensione | Formato | |
---|---|---|---|
2017 - Innovative pharmaceutical approaches for the management of inner ear disorders.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
853.67 kB
Formato
Adobe PDF
|
853.67 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
DDTR-D-17-00025_R1_2.pdf
Open Access dal 08/02/2018
Tipologia:
Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione
614.76 kB
Formato
Adobe PDF
|
614.76 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.